-
The pharmaceutical trade has a well-structured cycle.
-
Eli Lilly is at present benefiting from the early levels of the cycle.
-
In 10 years, if not sooner, buyers will start to fret about Eli Lilly’s future past GLP-1 medicine.
-
10 shares we like higher than Eli Lilly ›
For those who comply with the information in any respect, you realize that GLP-1 weight reduction medicine are having an enormous influence on society. The chief within the GLP-1 house right now is Eli Lilly (NYSE: LLY). That helps clarify why Wall Avenue is so excited concerning the firm’s inventory, pushing its price-to-earnings (P/E) ratio to a whopping 53 instances. There’s only one downside buyers want to grasp earlier than shopping for this drug maker.
Eli Lilly’s huge downside is not the valuation of its inventory. Nevertheless, the valuation is the start line for buyers who purchase it. And proper now, Eli Lilly’s inventory is dear. For comparability, the S&P 500 (SNPINDEX: ^GSPC) is buying and selling close to all-time highs, and the common P/E for the index is roughly 28 instances.
Nevertheless, a greater comparability level is likely to be different pharmaceutical shares. Utilizing iShares U.S. Prescribed drugs ETF (NYSEMKT: IHE) as an trade proxy, the common P/E for drugmakers is 30 instances. So, Eli Lilly’s 53 instances P/E ratio is properly above each the market and the common drug inventory.
In some methods, that valuation is sensible. Within the third quarter of 2025 alone, gross sales of Eli Lilly’s GLP-1 drug Mounjaro grew 109% yr over yr. Sister GLP-1 drug Zepbound grew much more, with a 185% income leap. That’s unbelievable development and reveals simply how a lot demand there may be for GLP-1 weight reduction medicine.
That stated, Mounjaro and Zepbound now make up over 50% of Eli Lilly’s prime line. The drugmaker is massively reliant on these two blockbuster medicine to assist its earnings assertion. That will not final, by design.
Pharmaceutical corporations are granted a restricted interval of exclusivity to promote a drug they develop. When that patent safety ends, generic drugmakers can start producing the identical drug, normally at a lower cost. When this occurs, the branded drug normally sees a fabric drop in gross sales. That is what’s known as a patent cliff. In a decade or so, buyers are prone to begin worrying about Eli Lilly dropping patent protections on its GLP-1 medicine.
Nevertheless, it might not take that lengthy for issues to begin exhibiting up. For instance, firstly of 2026, Novo Nordisk (NYSE: NVO) started promoting a tablet model of its Wegovy GLP-1 drug. Provided that Mounjaro and Zepbound are shot-based medicines, it would not be stunning to see a tablet model take market share.